Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  XOMA Corporation    XOMA

XOMA CORPORATION

(XOMA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
32.25(c) 32.68(c) 33.03(c) 32.5(c) 32.66 Last
22 621 64 148 60 874 18 366 29 150 Volume
+1.00% +1.33% +1.07% -1.60% +0.49% Change
More quotes
Financials (USD)
Sales 2020 18,9 M - -
Net income 2020 0,30 M - -
Net Debt 2020 - - -
P/E ratio 2020 1 219x
Yield 2020 -
Sales 2021 13,1 M - -
Net income 2021 -6,30 M - -
Net Debt 2021 - - -
P/E ratio 2021 -59,1x
Yield 2021 -
Capitalization 358 M 358 M -
Capi. / Sales 2020 18,9x
Capi. / Sales 2021 27,4x
Nbr of Employees 11
Free-Float 94,5%
More Financials
Company
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic... 
More about the company
Notations Surperformance© of XOMA Corporation
Trading Rating : Investor Rating :
More Ratings
All news about XOMA CORPORATION
11/17XOMA : Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase..
AQ
11/16XOMA CORP : Other Events (form 8-K)
AQ
11/16XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phas..
GL
11/16XOMA : Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase..
AQ
11/11AGENUS : XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
AQ
11/11XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
GL
11/05XOMA : 3Q Earnings Snapshot
AQ
11/05XOMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
11/05XOMA CORP : Results of Operations and Financial Condition, Financial Statements ..
AQ
11/05XOMA : Highlights Recent Royalty Asset Portfolio Developments and Reports Third ..
AQ
11/05XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third..
GL
11/04XOMA : Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Bein..
AQ
11/03BIOASIS TECHNOLOGIES : XOMA Acquires Royalty Interest in Four Lysosomal Storage ..
AQ
11/03XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Bei..
GL
10/29XOMA : Earns $25 Million Milestone Payment as Anti-TGF Antibody Enters Phase 2 C..
AQ
More news
News in other languages on XOMA CORPORATION
2019Principales informations avant-Bourse
2019L'américaine Xoma acquiert une participation dans une licence de Novartis
More news
Chart XOMA CORPORATION
Duration : Period :
XOMA Corporation Technical Analysis Chart | XOMA | US98419J2069 | MarketScreener
Technical analysis trends XOMA CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 29,50 $
Last Close Price 32,50 $
Spread / Highest target -7,69%
Spread / Average Target -9,23%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
James R. Neal Chief Executive Officer & Director
W. Denman van Ness Chairman
Thomas Burns Chief Financial Officer & Senior VP-Finance
Jack L. Wyszomierski Independent Director
Joseph M. Limber Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
XOMA CORPORATION19.05%358
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.55.32%38 761
BIONTECH SE200.68%24 529